<0> Nsight Public RelationsSandra Oak, 321-591-1508 </0>
, a biopharmaceutical company with the patented drug delivery technology , announced today that it has appointed ., as Chief Executive Officer and President. , President of , the innovation solutions company that funds and manages Caisson Biotech, stated that Caisson’s new partnerships and expansive growth drove the appointment of Dr. Nedwin, a seasoned veteran with an exceptional track record in strategic leadership and building company value.
“Caisson’s recent multi-million dollar technology access and license agreement with and increasing number of deals in the pipeline made the timing right to bring Dr. Nedwin on board,” explained Harlan. “Glenn’s comprehensive background in operations, business and product development, and market focus will take Caisson to the next level.”
Dr. Nedwin has more than 30 years experience in the pharmaceutical and biotechnology industries. He has held industry-influencing scientific and corporate management positions, most notably as President of Novozymes, Inc. and Executive Vice President of the Genencor Division of Danisco (recently acquired by DuPont). At Genencor he was responsible for the $330M+ Technical Enzyme Business Unit and was a member of the Danisco Leadership Forum. While with Genentech, Dr. Nedwin was a co-inventor and key team member that discovered TNF-alpha and -beta, among other human cytokines.
“I am very excited to join Caisson Biotech as CEO and President,” said Nedwin. “Caisson’s novel, natural HEPtune drug delivery technology for improved drug performance perfectly fits the needs of the pharmaceutical industry. HEPtune offers the ability for drug half-life extension and improvements in performance, product lifecycle management and patient quality of life. We are seeking additional corporate partners for our technology and we intend to become a leader in drug delivery.”
Dr. Nedwin brings to Caisson substantial domestic and international experience with start-up, growth and global organizations in the areas of new market identification, innovation, R&D, P&L, sales and marketing. Co-author of more than 30 scientific publications and patents, he is co-editor in chief of the journal . He serves on the Emergent Technologies, Inc. Board of Directors. Dr. Nedwin holds a Bachelor of Science in Biochemistry from the State University of New York College at Buffalo, a Masters Degree in the Management of Technology from Massachusetts Institute of Technology Sloan School of Management, and a Ph.D. in Biochemistry from the University of California, Riverside.
Caisson Biotech is a wholly-owned subsidiary of Heparinex, L.L.C. Caisson uses novel, heparosan-based conjugates to enhance the therapeutic properties of pharmaceuticals by increasing product half-life, reducing immunogenicity and increasing stability. The newly invented drug delivery platform was developed by Chief Scientist ., who is also a Professor at the University of Oklahoma Health Sciences Center.
Caisson is funded and managed by Emergent Technologies, Inc. To learn more about Caisson, visit .
Emergent Technologies, Inc. (Emergent) is a leading innovation solutions company focused on partnering early stage technologies. Emergent's diverse business and technical team, along with its unique innovation process of transforming scientific breakthroughs into technology platforms with multiple applications, maximizes the value of promising ideas and underutilized intellectual properties without the risk associated with commercial development. Emergent applies its experience and expertise to provide investors, entrepreneurs, communities and industry partners access to innovative solutions to advance initiatives and protect and grow core businesses with novel, differentiating technology. For more information, visit the Emergent website .